IPCP-KENYA: PrEP Delivery in High-Risk Populations

Open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by LVCT Health. Primary endpoints: Number of young women, female sex workers and men who have sex with men correctly identified as being at high risk of HIV at 4 months, Proportion of participants enrolled into a HIV combination prevention intervention package that includes PrEP at 4 months and 6 more. Status: unknown.